expression of proliferation markers including- Ets1, keratin 6 (K6), Ki67, and DeltaNp63. Found at: doi:10.1371/journal.pone.0004179.s003 (1.96 MB TIF) Acknowledgments We thank Kirsten Smalley and Irene Kulik for excellent technical assistance. We also thank Dr. Jeffrey Davidson and Dr. Keith Kirkwood for MMP13 reporter plasmids. References 1. Pons M, Quintanilla M (2006) Molecular biology of malignant melanoma and other cutaneous tumors. Clin Transl Oncol 8: 466–474. 2. Hussein MR (2005) Ultraviolet radiation and skin cancer: molecular mechanisms. J Cutan Pathol 32: 191–205. 3. Keehn CA, Smoller BR, Morgan MB (2004) Ets-1 immunohistochemical expression in non-melanoma skin carcinoma. J Cutan Pathol 31: 8–13. 4. Pande P, Mathur M, Shukla NK, Ralhan R (1999) Ets-1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas. J Pathol 189: 40–45. 5. Saeki H, Kuwano H, Kawaguchi H, Ohno S, Sugimachi K (2000) Expression of ets-1 transcription factor is correlated with penetrating tumor progression in patients with squamous cell carcinoma of the esophagus. Cancer 89: 1670–1676. 6. Mukherjee T, Kumar A, Mathur M, Chattopadhyay TK, Ralhan R (2003) Ets-1 and VEGF expression correlates with tumor angiogenesis, lymph node metastasis, and patient survival in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 129: 430–436. 7. Horvath B, Hegyesi H, Nagy P, Falus A, Schaff Z (2005) Expression of ets-1 transcription factor in human head and neck squamous cell carcinoma and effect of histamine on metastatic potential of invasive tumor through the regulation of expression of ets-1 and matrix metalloproteinase-3. Head Neck. 8. Endo K, Shirai A, Furukawa M, Yoshizaki T (2006) Prognostic value of cell motility activation factors in patients with tongue squamous cell carcinoma. Hum Pathol 37: 1111–1116. 9. Vairaktaris E, Goutzanis L, Kalokerinos G, Yannopoulos A, Yapijakis C, et al. (2007) Diabetes increases both N-ras and ets-1 expression during rat oral oncogenesis resulting in enhanced cell proliferation and metastatic potential. In Vivo 21: 615–621. 10. Vairaktaris E, Papageorgiou G, Derka S, Moulavassili P, Nkenke E, et al. (2007) Expression of ets-1 is not affected by N-ras or H-ras during oral oncogenesis. J Cancer Res Clin Oncol 133: 227–233. 11. Wasylyk C, Gutman A, Nicholson R, Wasylyk B (1991) The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non- nuclear oncoproteins. Embo J 10: 1127–1134. 12. Westermarck J, Seth A, Kahari VM (1997) Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 14: 2651–2660. 13. Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, et al. (1998) The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int J Cancer 77: 128–137. 14. Baillat D, Begue A, Stehelin D, Aumercier M (2002) ETS-1 Transcription Factor Binds Cooperatively to the Palindromic Head to Head ETS-binding Sites of the Stromelysin-1 Promoter by Counteracting Autoinhibition. J Biol Chem 277: 29386–29398. 15. Reisdorff J, En-Nia A, Stefanidis I, Floege J, Lovett DH, et al. (2002) Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. J Am Soc Nephrol 13: 1568–1578. 16. Quinn CO, Rajakumar RA, Agapova OA (2000) Parathyroid hormone induces rat interstitial collagenase mRNA through Ets-1 facilitated by cyclic AMP response element-binding protein and Ca(2+)/calmodulin-dependent protein kinase II in osteoblastic cells. J Mol Endocrinol 25: 73–84. 17. Ries S, Biederer C, Woods D, Shifman O, Shirasawa S, et al. (2000) Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103: 321–330. 18. Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW (1994) Dual control of myc expression through a single DNA binding site targeted by ets family proteins and E2F-1. Oncogene 9: 405–415. 19. Coffer P, de Jonge M, Mettouchi A, Binetruy B, Ghysdael J, et al. (1994) junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2. Oncogene 9: 911–921. 20. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, et al. (2001) Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067–1070. 21. Zhang C, Kavurma MM, Lai A, Khachigian LM (2003) Ets-1 protects vascular smooth muscle cells from undergoing apoptosis by activating p21WAF1/Cip1: ETS-1 regulates basal and and inducible p21WAF1/Cip: ETS-1 regulates basal and inducible p21WAF1/Cip1 transcription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J Biol Chem 278: 27903–27909. 22. Kahle A, Feng Y, M AN (2005) Isolation and characterization of the human Cdc2L1 gene promoter. Gene 344: 53–60. Ets1 in Squamous Neoplasia Author Contributions Conceived and designed the experiments: PN NP LAGS SS. Performed the experiments: PN NP LAGS. Analyzed the data: PN NP LAGS SS. Contributed reagents/materials/analysis tools: SS. Wrote the paper: PN LAGS SS. 23. Li R, Pei H, Watson DK, Papas TS (2000) EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes. Oncogene 19: 745–753. 24. Kavurma MM, Bobryshev YV, Khachigian LM (2002) Ets-1 positively regulates Fas ligand transcription via co-operative interactions with Sp1. J Biol Chem. 25. Seth A, Giunta S, Franceschil C, Kola I, Venanzoni MC (1999) Regulation of the human stress response gene GADD153 expression: role of ETS1 and FLI-1 gene products. Cell Death Differ 6: 902–907. 26. Venanzoni MC, Robinson LR, Hodge DR, Kola I, Seth A (1996) ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction. Oncogene 12: 1199–1204. 27. Lai HC, Chu CM, Lin YW, Chang CC, Nieh S, et al. (2005) Matrix metalloproteinase 1 gene polymorphism as a prognostic predictor of invasive cervical cancer. Gynecol Oncol 96: 314–319. 28. Nakazawa Y, Suzuki M, Manabe N, Yamada T, Kihara-Negishi F, et al. (2007) Cooperative interaction between ETS1 and GFI1 transcription factors in the repression of Bax gene expression. Oncogene. 29. Salnikow K, Aprelikova O, Ivanov S, Tackett S, Kaczmarek M, et al. (2008) Regulation of Hypoxia-inducible Genes by ETS1 Transcription Factor. Carcinogenesis. 30. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, et al. (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359–39367. 31. Xu D, Wilson TJ, Chan D, De Luca E, Zhou J, et al. (2002) Ets1 is required for p53 transcriptional activity in UV-induced apoptosis in embryonic stem cells. Embo J 21: 4081–4093. 32. Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, et al. (2003) Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 22: 7716–7727. 33. Gu L, Zhu N, Findley HW, Woods WG, Zhou M (2004) Identification and characterization of the IKKalpha promoter: positive and negative regulation by ETS-1 and p53, respectively. J Biol Chem 279: 52141–52149. 34. Lee S, Das HK (2008) Inhibition of basal activity of c-jun-NH2-terminal kinase (JNK) represses the expression of presenilin-1 by a p53-dependent mechanism. Brain Res 1207: 19–31. 35. Maroulakou IG, Papas TS, Green JE (1994) Differential expression of ets-1 and ets-2 proto-oncogenes during murine embryogenesis. Oncogene 9: 1551–1565. 36. Yamamoto H, Flannery ML, Kupriyanov S, Pearce J, McKercher SR, et al. (1998) Defective trophoblast function in mice with a targeted mutation of Ets2. Genes Dev 12: 1315–1326. 37. Jaubert J, Patel S, Cheng J, Segre JA (2004) Tetracycline-regulated transactivators driven by the involucrin promoter to achieve epidermal conditional gene expression. J Invest Dermatol 123: 313–318. 38. Senoo M, Pinto F, Crum CP, McKeon F (2007) p63 Is essential for the proliferative potential of stem cells in stratified epithelia. Cell 129: 523–536. 39. Parsa R, Yang A, McKeon F, Green H (1999) Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 113: 1099–1105. 40. Reis-Filho JS, Torio B, Albergaria A, Schmitt FC (2002) p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 29: 517–523. 41. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA (2006) Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res 66: 7589–7597. 42. Lo Muzio L, Santarelli A, Caltabiano R, Rubini C, Pieramici T, et al. (2005) p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 36: 187–194. 43. Ala-aho R, Kahari VM (2005) Collagenases in cancer. Biochimie 87: 273–286. 44. Akgul B, Pfefferle R, Marcuzzi GP, Zigrino P, Krieg T, et al. (2006) Expression of matrix metalloproteinase (MMP)-2, MMP-9, MMP-13, and MT1-MMP in skin tumors of human papillomavirus type 8 transgenic mice. Exp Dermatol 15: 35–42. 45. Hartenstein B, Dittrich BT, Stickens D, Heyer B, Vu TH, et al. (2006) Epidermal development and wound healing in matrix metalloproteinase 13- deficient mice. J Invest Dermatol 126: 486–496. 46. Impola U, Jeskanen L, Ravanti L, Syrjanen S, Baldursson B, et al. (2005) Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds. Br J Dermatol 152: 720–726. PLoS ONE | www.plosone.org 14 January 2009 | Volume 4 | Issue 1 | e4179